



MEDI-CAL DRUG USE REVIEW (DUR) BOARD

State of California
DEPARTMENT OF HEALTH CARE SERVICES

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, February 12, 2013**, at the following location:

Department of Health Care Services
 1500 Capitol Avenue
 Training Rooms B+C
 Sacramento, CA 95814

Medi-Cal Drug Use Review Board
 Meeting Agenda
 February 12, 2013
 10:30 a.m. - 1:00 p.m.

Report Type*	Agenda Item	Presenter	Time
C	1. Welcome/Introduction	Pauline Chan, RPh	1030-1040
A	2. Call to Order/Review and Approval of Previous Minutes November 13, 2012	Marilyn Stebbins, Pharm.D.	1040-1045
	3. Old Business		
A	a. Review of Action Items From Previous Board Meeting: <ul style="list-style-type: none"> i. DUR's role in Medi-Cal FFS and the transition of FFS to Medi-Cal Managed Care Program ii. MIS/DSS Update iii. Video meeting capabilities for future board meetings iv. What is feasible to report on as it relates to drug costs v. When/where Medi-Cal population got flu vaccination 	Pauline Chan, RPh	1045-1055
	4. New Business		
R	a. Board activities: <ul style="list-style-type: none"> i. Strategic planning conference call ii. Depression and treatment patterns during pregnancy and postpartum 	Marilyn Stebbins, Pharm.D. Patrick Finley, Pharm. D.	1055-1105 1105-1110
R	b. DHCS Quality Strategy	Desiree Backman,	1110-

		Ph.D, Chief Prevention Officer	1140
	<p>c. Quarterly Report – 3Q2012 (July - September 2012)</p> <p>d. Research Topics and Action Items from the Previous Meeting</p> <p>i. Compare utilization for all atypical antipsychotic injections</p> <p>e. Prospective DUR</p> <p>i. Review of DUR Alert: Drug/Allergy (DA)</p> <p>ii. Review of Prospective DUR Criteria</p> <p>1. Maximum quantity restrictions: triptans</p> <p>f. Retrospective DUR</p> <p>i. Review of Retrospective DUR Criteria</p> <p>1. Migraine quality of care: triptans</p> <p>2. Annual monitoring of persistent use medications: anticonvulsants, ACE inhibitors/ARBs, diuretics, and digoxin</p> <p>3. Comprehensive diabetes care: insulin or oral hypoglycemics/anti-hyperglycemics</p> <p>4. Drug/drug interaction: Beta blockers and CYP 2D6 inhibitors</p> <p>ii. Discussion/Recommendations for Future Educational Bulletins</p> <p>g. Electronic Prescribing Update – Partners in E program</p>	Amanda Smith, MPH	1140-1155
		Shalini Lynch, Pharm.D.	1155-1225
		Sokkim Lim, Pharm.D.	1225-1240
R	<p>h. DHCS Update</p> <p>i. Contract Drug List Look Up Tool</p> <p>ii. Medi-Cal subscription</p>	Pauline Chan, RPh.	1240-1255
C	5. Public Comments		1255-1300
	6. Consent Agenda		
I	<p>i. Meeting feedback</p> <p>j. Next meeting May 14, 2013: 10:30 a.m. -1 p.m. DHCS Training Room B+C Sacramento, CA 95814</p>		
	7. Adjournment		1300

* REPORT TYPE LEGEND: A: Action; R: Report; I: Information; C: Comment; D: Discussion

** Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu website (http://files.medi-cal.ca.gov/pubsdoco/dur/dur_home.asp).